Mika Okazawa-Sakai

6PUBLICATIONS
45CO-AUTHORS
Predictive and prognostic markersCancer geneticsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Aug 07, 2026
cfDNA-inferred putative clonal hematopoiesis during first-line platinum-to-PARP inhibitor maintenance in ovarian cancer.

|Nov 11, 2025
Current management of hereditary cancer syndromes in ovarian and endometrial cancer: a Japanese study.

Takanori Yokoyama, Yasuko Yamamoto, Mika Okazawa-Sakai

|Oct 25, 2024
Gut microbiome associated with PARP inhibitor efficacy in patients with ovarian cancer.

Mika Okazawa-Sakai, Shunsuke A Sakai, Ichinosuke Hyodo

|Aug 29, 2022
Frequency and clinical features of deficient mismatch repair in ovarian clear cell and endometrioid carcinoma.

Tamaki Tanaka, Kazuhiro Takehara, Natsumi Yamashita

|Feb 16, 2018
Long-term outcomes of postoperative taxane/platinum chemotherapy for early stage cervical cancer: a retrospective study.

Mika Okazawa-Sakai, Takanori Yokoyama, Etsuko Fujimoto

|Dec 14, 2016
Chemoradiotherapy followed by consolidation chemotherapy involving paclitaxel and carboplatin and in FIGO stage IIIB/IVA cervical cancer patients.

Seiji Mabuchi, Fumiaki Isohashi, Mika Okazawa

Pageof 1

Frequent Collaborators

4 joint publications

Kazuhiro Takehara

2 joint publications

Yoh Hayasaki

2 joint publications

Kimihiko Ito

2 joint publications

Daisuke Shintani